Introduction
============

Tracheal extubation is commonly performed during the emergence phase after stopping anesthetics. Significant systemic stress responses to pain and airway stimulation can occur during this period, including agitation and cough, which may cause hypertension, tachycardia, and increased intracranial hypertension.[@b1-jpr-10-933] This not only greatly increases the discomfort of patients but it also increases the rates of angiocardiopathy and other side effects. Gacouin et al[@b2-jpr-10-933] evaluated 203 patients' pain using a visual analog scale (VAS), and they found \>73% of patients experienced moderate or severe pain during extubation. Traditionally, anesthetic withdrawal involves discontinuing both propofol and remifentanil, which can result in pain experienced by patients in an unawakened state and which can lead to a stress response induced by the tracheal catheter. This widely increases the probability of dysphoria and adverse reactions during the peri-extubation period. Therefore, it is extremely important to identify a method to effectively reduce the stress response during peri-extubation.

Remifentanil is a new ultra-short-acting opioid μ-receptor stimulant, with rapid onset and offset activity, which can also be rapidly hydrolyzed in tissue and blood with no dependence on liver and kidney function.[@b3-jpr-10-933] Continuous infusion of remifentanil has no prolonged context-sensitive half-time or cumulative effects,[@b4-jpr-10-933] which makes it easier to maintain a stable concentration at the effect site. Therefore, remifentanil is widely used for clinical anesthesia.[@b5-jpr-10-933] Remifentanil not only has an anesthetic and analgesic effect but it can also reduce the incidence of respiratory depression and other adverse reactions. The use of a continuous infusion of remifentanil after total intravenous anesthesia has multiple advantages, as remifentanil can be used to control excessive stress responses.[@b6-jpr-10-933] Aouad et al[@b7-jpr-10-933] showed that the use of a small dose of remifentanil did not prolong the time taken to wake up from anesthesia, and it decreased the occurrence of cough during the emergence phase.

As a previous study showed, the use of remifentanil often results in postoperative discomfort and hyperalgesia.[@b8-jpr-10-933] Therefore, a long-acting postoperative analgesic is of urgent need to avoid postoperative hyperalgesia and pain caused by remifentanil. Parecoxib is a new nonsteroidal anti-inflammatory drug (NSAID) that has selective cyclooxygenase-2 inhibitory activity, strong anti-inflammatory analgesic activity, long-term efficacy,[@b8-jpr-10-933] and minimal cardiovascular risk.[@b9-jpr-10-933] Many studies have shown that NSAIDs can ameliorate the side effects caused by opioids, including respiratory depression, nausea, emesis, and somnolence,[@b10-jpr-10-933] so parecoxib is often used as a postoperative analgesic.

Until now, the appropriate dose of remifentanil for inhibiting stress responses has remained unclear. The stress response that occurs during major surgeries is not only related to the irritation caused by the endotracheal tube but also to the surgical stimulation of patients during the emergence phase. Therefore, this study aimed to explore the combined effect of parecoxib with different doses of remifentanil on hemodynamic vital signs and stress responses to extubation.

Patients and methods
====================

Patients
--------

We obtained approval from the institutional review board of the First Affiliated Hospital of Kunming Medical University, People's Republic of China, and written informed consent from the patients. A total of 120 patients with American Society of Anesthesiologists scores of I or II, who were 20--50 years old and weighed 40--75 kg, were selected to take part in the study, which involved elective thyroidectomy with general anesthesia and tracheal intubation. Patients with the following characteristics were excluded from the study: patients with an allergy to opioids or NSAIDs, hypertension, a history of ischemic heart disease, or a history of cerebrovascular disease. The included patients were randomly divided into four groups with 30 patients per group: control group, low-dose remifentanil group (R1), medium-dose remifentanil group (R2), and high-dose remifentanil group (R3).

Procedure
---------

After entering the operating room, the blood pressure (BP), heart rate (HR), respiratory rate (R), and peripheral arterial oxygen saturation (SPO~2~) of each patient were routinely monitored. The venous channel was opened and an isotonic saline solution (10 ml/kg/h) was administered. After the patient reached a stable condition, anesthesia induction was performed. For the patients in all four groups, this involved the intravenous infusion of fentanyl (4 μg/kg), rocuronium bromide (0.6 mg/kg), and propofol (2.5 mg/kg).

Then anesthesia was maintained using a venous perfusion of propofol (6--12 mg/kg/h) and remifentanil (0.1--0.5 μg/kg/min) before the incision suture. The doses were changed according to each patient's response. When suturing the incision, the patients in all four groups received an intravenous infusion of parecoxib (40 mg) and an intravenous drip of tropisetron (4 mg). The patients in the control group received an isotonic saline injection (instead of propofol and remifentanil). In contrast, the patients in groups R1, R2, and R3 were treated with intravenous remifentanil at 0.1 μg/kg/min, 0.2 μg/kg/min, and 0.3 μg/kg/min, respectively.

After the operation, the patients' responses to commands were monitored every 2 min. Patients who could open their eyes on command and responded to commands were assessed as being conscious. Extubation and discontinuation of remifentanil were initiated when the patients had the following conditions: response to commands, spontaneous respiration, deglutition reflex, tidal volume \>8 ml/kg, respiratory rate \>10 times/min, and SPO~2~ \>95%.

Observation indexes
-------------------

The BP, HR, R, and SPO~2~ of each patient were monitored before anesthesia induction (at baseline), and these indexes were also monitored when the patient was in a waking state, at extubation, and at 2, 5, 10, and 15 min after extubation. The emergence time was defined as the time between discontinuation of propofol and the point at which the patient regained consciousness. The extubation time was defined as time between the discontinuation of propofol and extubation. The operation, emergence, and extubation times of each patient were recorded. The times and severity of cough during the extubation time were recorded. Anesthesia-, extubation-, and remifentanil-related adverse reactions were also recorded, which included intraoperative awareness, comfort level during extubation, cough, laryngospasm, encephalalgia, dizziness, nausea, emesis, uroschesis, and skin pruritus. Furthermore, the sedation-agitation scale (SAS; 1 = unarousable; 7 = dangerous agitation)[@b11-jpr-10-933] and the pain VAS at 0 min (i.e., the time at which the patient regained consciousness), and 5, 10, and 15 min after recovery of consciousness, were recorded to evaluate the patients' sedation levels.

Statistical analysis
--------------------

Statistical analyses were performed using SPSS 17.0 statistical software (SPSS Inc., Chicago, IL, USA). The qualitative data are presented as frequencies (with percentages), and comparison among the groups was performed using chi-square tests with α = 0.05. A normality test was carried out for each quantitative variable. The normally distributed data are presented as mean ± standard deviation, and comparison among the groups was performed using one-way analysis of variance (ANOVA). The non-normally distributed data are presented as medians (with ranges), and comparison among the groups was performed using nonparametric tests. Repeated-measures analyses of the effects of the different treatments and times on the SAS and VAS scores were performed using generalized estimating equations (GEEs). We selected α = 0.05 as the standard level of significance and so *P* \< 0.05 was considered statistically significant.

Results
=======

In this study, 120 patients were selected and there were 30 patients in each group. As shown, gender, age, surgical time, nausea, emesis, dizziness, headache, intraoperative awareness, and uroschesis in the control, R1, R2, and R3 groups were not significantly different ([Table 1](#t1-jpr-10-933){ref-type="table"}). The emergence and extubation times were different among the groups, with increases in remifentanil dose, and considerably longer times in group R2 (remifentanil at 0.2 μg/kg/min) and group R3 (remifentanil at 0.3 μg/kg/min) compared to the time in group R1 (remifentanil at 0.1 μg/kg/min) and control group (*P* \< 0.05). The number of patients with a cough in each group decreased with remifentanil dose, and the differences were significant (21 in the control group, 18 in group R1, 8 in group R2, and 3 in group R3, *P* = 0.000). The number of patients with respiratory depression was higher in the group with the highest dose of remifentanil (1 in groups R1 and R2 and 7 in group R3, *P* = 0.002). The number of patients in each group unknown about the extubation increased with the remifentanil dose, and all the patients in groups R2 and R3 knew about extubation (14, 25, 30, and 30 in the control, R1, R2, and R3 groups, respectively, *P* = 0.000). Only 10% of patients in group R3 had bradycardia and 9% of patients in the control group experienced intolerable discomfort with extubation. A small number of patients in the control and low-dose remifentanil groups were aware but did not experience discomfort (13.3%) or experienced tolerable discomfort (10%) ([Table 1](#t1-jpr-10-933){ref-type="table"}). These results indicated that continuous postoperative infusion of remifentanil can not only reduce coughing and discomfort responses to extubation but they can also increase respiratory depression and bradycardia.

The SAS and VAS scores of the patients in each group were recorded at emergence time (0 min) and at 5, 10, and 15 min after emergence. These data were analyzed using GEEs, and the results are shown in [Tables 2](#t2-jpr-10-933){ref-type="table"}[](#t3-jpr-10-933){ref-type="table"}[](#t4-jpr-10-933){ref-type="table"}--[5](#t5-jpr-10-933){ref-type="table"}, respectively. There were significant differences in the SAS scores among the groups (Wald *χ*^2^ = 17.986, *P* = 0.000), and the odds ratios (ORs) of groups R1, R2, and R3 were 0.163, 0.246, and 0.887, respectively, compared with the control group, indicating that the SAS score decreased with the remifentanil dose. The SAS scores at different times were also statistically different (Wald *χ*^2^ = 74.983, *P* = 0.000), and the ORs at 5, 10, and 15 min were 0.004, 0.000, and 0.000, respectively, compared with at 0 min, indicating that the SAS scores increased with time after emergence. Furthermore, the VAS score analysis showed that the VAS score was associated with the remifentanil dose (Wald *χ*^2^ = 32.668, *P* = 0.000) and time (Wald *χ*^2^ = 142.554, *P* = 0.000). The VAS score was highest in group R1 (OR = 10.298, 5.183, and 5.844 in groups R1, R2, and R3, respectively) and it increased with time (OR = 0.031, 0.007, and 0.002 at 5, 10, and 15 min, respectively).

The cardiovascular vital signs (systolic and diastolic BP, HR, R, and SPO~2~) of the patients in each group were monitored at baseline, emergence, extubation, and 2, 5, 10, and 15 min after extubation. Compared with baseline, the systolic and diastolic BP, HR, and SPO~2~ in the control group all clearly increased at emergence, extubation, and after extubation (*P* \< 0.05), but R was significantly reduced at emergence, extubation, and after extubation (*P* \< 0.05). In the R1 group, the diastolic BP decreased only 5 min after extubation (*P* \< 0.05) and HR dramatically increased at extubation (*P* \< 0.05). Systolic and diastolic BP decreased at emergence in the R2 and R3 groups (*P* \< 0.05). HR increased 5 min after extubation in the R2 group (*P* \< 0.05), and it decreased at emergence but increased at 5, 10, and 15 min after extubation in the R3 group (*P* \< 0.05). The R and SPO~2~ decreased and increased, respectively, in the R1, R2, and R3 groups (*P* \< 0.05). Compared with the control group, the systolic and diastolic BP in the remifentanil groups was significantly lower at emergence, extubation, and 2 and 5 min after extubation (*P* \< 0.05). The HR of the remifentanil groups greatly decreased at emergence, extubation, and 2 min after extubation (*P* \< 0.05). The SPO~2~ of the remifentanil groups showed no significant change ([Table 6](#t6-jpr-10-933){ref-type="table"}). These results suggest that postoperative remifentanil infusions can decrease the rise in systolic and diastolic BP, HR, and R at emergence and extubation, and they showed that the effect of a high dose of remifentanil on these variables was longer and better.

Discussion
==========

Many studies have been carried out to explore the methods that can effectively alleviate stress responses, agitation, and discomfort due to tracheal extubation during the emergence time from general anesthesia. Vasoactive drugs, such as esmolol and ebrantil, can be used to inhibit cardiovascular responses to tracheal extubation. However, they can only improve tachycardia and hyperpiesia, and fail to inhibit the intense stimulation of the trachea by the tracheal catheter and to effectively stop the agitation and discomfort during the peri-extubation period.[@b12-jpr-10-933] Long-acting opioid analgesics, such as fentanyl, sufentanil, and dezocine, have been used during the peri-extubation period to inhibit stress responses and discomfort, and they have been shown to have some effect. However, the controllability of long-acting opioid analgesics is poor due to longer elimination half-life and prolonged context-sensitive half-life. The use of fentanyl can not only reduce stress responses but it can also induce respiratory depression and delay recovery.[@b13-jpr-10-933]

Remifentanil is a new kind of ultra-short-acting opioid analgesic. It has many advantages such as rapid onset, shorter elimination half-life, no accumulation after long-term application, no effect caused by impaired hepatorenal function, and no prolonged context-sensitive half-life.[@b14-jpr-10-933],[@b15-jpr-10-933] Therefore, remifentanil may be the most easily controllable opioid analgesic. In our study, continuous injection of remifentanil after surgery decreased the number of patients with coughs and increased the patients' comfort during emergence from general anesthesia and extubation, though it also prolonged the emergence and extubation times. Furthermore, the patients treated with remifentanil had no significant adverse effects such as nausea, emesis, dizziness, headache, or uroschesis. The occurrence rates of cough and discomfort were effectively reduced, and there was no obvious occurrence of respiratory depression or bradycardia among the patients treated with remifentanil at 0.2 μg/kg/min after surgery. The fact that continuous injection of remifentanil after surgery can inhibit airway reflex and attenuate the stimulus of tracheal tube may account for the result.[@b7-jpr-10-933],[@b16-jpr-10-933]

Previous research has suggested that remifentanil does not cause a decrease in the bispectral index value,[@b17-jpr-10-933] which may be inversely correlated with the level of analgesia.[@b18-jpr-10-933] The SAS and VAS results in this study showed that the sedative and analgesic effects were enhanced by increased doses of remifentanil, indicating that continuous postoperative infusion of remifentanil can effectively relieve postoperative pain.[@b19-jpr-10-933] In addition, the analysis of hemodynamic vital signs showed that continuous postoperative infusion of remifentanil inhibited the elevation of systolic and diastolic BP during the peri-extubation period and that using a high dose of remifentanil (0.3 μg/kg/min) delayed the rise in HR. This demonstrates that the postoperative use of a low dose of remifentanil can ameliorate any changes in BP and HR during the peri-extubation period, and it has beneficial effects on hemodynamic stability.[@b20-jpr-10-933] However, the sedative and analgesic effects and hemodynamic stability were not only enhanced with the dose of remifentanil, but they also reduced with time, which suggests that the comfort of patients during the peri-extubation period was associated with the remifentanil dose[@b21-jpr-10-933] and its short time of offset.[@b22-jpr-10-933] Moreover, the slight changes in BP and HR caused by remifentanil can return to their original levels within 5--10 min without treatment.[@b23-jpr-10-933]

Conclusion
==========

In our study, we showed that continuous infusion of remifentanil during peri-extubation period can effectively suppress stress and coughing responses and improve patients' comfort during the emergence phase. Furthermore, use of remifentanil at 0.2 μg/kg/min reduced the rate of side effects compared to that at 0.3 μg/kg/min, and it may be appropriate for inhibiting stress responses to tracheal extubation under general anesthesia. Therefore, continuous postoperative infusion of remifentanil at a dose of 0.2 μg/kg/min may be safe and comfort for tracheal extubation.
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###### 

Comparison of patient characteristics and postoperative complications

  Variable                                Group C                                                          Group R1                                                         Group R2                                                         Group R3                                                        *P*
  --------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- ---------------------------------------------------------------- --------------------------------------------------------------- -------
  Gender, n (%)                                                                                                                                                                                                                                                                                              0.065
   Male                                   3 (10.0%)                                                        10 (33.3%)                                                       11 (36.7%)                                                       6 (20.0%)                                                       --
   Female                                 27 (90.0%)                                                       20 (66.7%)                                                       19 (63.3%)                                                       24 (80.0%)                                                      --
  Age, mean ± SD                          40.47 ± 11.65[a](#tfn2-jpr-10-933){ref-type="table-fn"}          43.6 ± 12.24[a](#tfn2-jpr-10-933){ref-type="table-fn"}           42.1 ± 12.44[a](#tfn2-jpr-10-933){ref-type="table-fn"}           37.53 ± 11.13[a](#tfn2-jpr-10-933){ref-type="table-fn"}         0.236
  BMI, median (range)                     21.92 (17.99, 25.97)[a](#tfn2-jpr-10-933){ref-type="table-fn"}   22.72 (16.61, 30.45)[a](#tfn2-jpr-10-933){ref-type="table-fn"}   23.83 (17.97, 29.76)[a](#tfn2-jpr-10-933){ref-type="table-fn"}   22.1 (17.69, 29.52)[a](#tfn2-jpr-10-933){ref-type="table-fn"}   0.046
  Surgical time (min), median (range)     115 (60, 215)                                                    107.5 (50, 240)                                                  122.5 (45, 315)                                                  125 (70, 210)                                                   0.264
  Emergence time (min), median (range)    12 (6, 23)[a](#tfn2-jpr-10-933){ref-type="table-fn"}             15 (6, 30)[a,c](#tfn2-jpr-10-933){ref-type="table-fn"}           20 (14, 30)[b,c](#tfn2-jpr-10-933){ref-type="table-fn"}          25.5 (15, 45)[b](#tfn2-jpr-10-933){ref-type="table-fn"}         0.000
  Extubation time (min), median (range)   16 (16, 16)[a](#tfn2-jpr-10-933){ref-type="table-fn"}            18 (8, 35)[a,c](#tfn2-jpr-10-933){ref-type="table-fn"}           23 (9, 36)[b,c](#tfn2-jpr-10-933){ref-type="table-fn"}           31.5 (17, 47)[b](#tfn2-jpr-10-933){ref-type="table-fn"}         0.000
  Cough, n (%)                            21 (70.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}             18 (60.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}             8 (27.7%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}              3 (10.0%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}             0.000
  Respiratory depression, n (%)           0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      1 (3.3%)[a,b](#tfn2-jpr-10-933){ref-type="table-fn"}             1 (3.3%)[a,b](#tfn2-jpr-10-933){ref-type="table-fn"}             7 (23.3%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}             0.002
  Bradycardia, n (%)                      0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      3 (10.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}             0.027
  Muscle rigidity, n (%)                  0                                                                0                                                                0                                                                0                                                               --
  Nausea and emesis, n (%)                14 (48.3%)                                                       8 (27.7%)                                                        11 (36.7%)                                                       10 (33.3%)                                                      0.144
  Dizziness headache, n (%)               10 (33.3%)                                                       11 (36.7%)                                                       9 (30.0%)                                                        6 (20.7%)                                                       0.244
  Intraoperative awareness, n (%)         1 (3.3%)                                                         1 (3.3%)                                                         2 (6.9%)                                                         0                                                               0.659
  Uroschesis, n (%)                       4 (13.3%)                                                        5 (16.7%)                                                        2 (6.7%)                                                         1 (3.3%)                                                        0.104
  Unknown about extubation, n (%)         14 (46.7%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}             25 (83.3%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}             30 (100%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}              30 (100%)[b](#tfn2-jpr-10-933){ref-type="table-fn"}             0.000
  Awareness with comfort, n (%)           4 (13.3%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}              3 (10.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}              0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                     0.009
  Tolerable discomfort, n (%)             4 (13.3%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}              3 (10.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}              0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[a](#tfn2-jpr-10-933){ref-type="table-fn"}                     0.009
  Intolerable discomfort, n (%)           9 (30.0%)[a](#tfn2-jpr-10-933){ref-type="table-fn"}              0[b](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[b](#tfn2-jpr-10-933){ref-type="table-fn"}                      0[b](#tfn2-jpr-10-933){ref-type="table-fn"}                     0.000

**Notes:** *P* \< 0.05 is considered as statistically significant.

The results of two comparisons; no significant statistical difference between two groups with same letter, but significant statistical differences between two groups with different letters.

**Abbreviations:** BMI, body mass index; C, sodium chloride; R1, remifentanil (0.1 µg/kg/min); R2, remifentanil (0.2 µg/kg/min); R3, remifentanil (0.3 µg/kg/min).

###### 

Number (percentage) of SAS

  Emergence time   Score        Group C, n (%)   Group R1, n (%)   Group R2, n (%)   Group R3, n (%)
  ---------------- ------------ ---------------- ----------------- ----------------- -----------------
  0 min            3            19 (63.3%)       6 (20%)           9 (30%)           16 (53.3%)
  4                11 (36.7%)   24 (80%)         21 (70%)          14 (46.7%)        
  5 min            3            1 (3.3%)         0                 0                 0
  4                19 (63.3%)   9 (30%)          11 (37.9%)        24 (80%)          
  5                10 (33.3%)   21 (70%)         18 (62.1%)        6 (20%)           
  10 min           4            1 (3.3%)         1 (3.3%)          0                 0
  5                29 (96.7%)   29 (96.7%)       30 (100%)         30 (100%)         
  15 min           4            1 (3.3%)         0                 0                 0
  5                29 (96.7%)   28 (96.6%)       30 (100%)         30 (100%)         
  6                0            1 (3.4%)         0                 0                 

**Abbreviations:** C, sodium chloride; R1, remifentanil (0.1 μg/kg/min); R2, remifentanil (0.2 μg/kg/min); R3, remifentanil (0.3 μg/kg/min); SAS, sedation-agitation scale.

###### 

Correlation between SAS and the dose and infusion time of remifentanil

  Parameters     B                                             OR      95%CI of OR   Hypothesis test                 
  -------------- --------------------------------------------- ------- ------------- ----------------- --------- --- -------
  SAS = 6.00     −17.197                                       0.000   0.000         0.000             114.564   1   0.000
  SAS = 5.00     −6.508                                        0.001   0.000         0.011             40.884    1   0.000
  SAS = 4.00     −.456                                         0.634   0.292         1.375             1.332     1   0.248
  Group = R3     −.120                                         0.887   0.335         2.351             0.058     1   0.810
  Group = R2     −1.404                                        0.246   0.090         0.674             7.436     1   0.006
  Group = R1     −1.813                                        0.163   0.053         0.503             9.965     1   0.002
  Group = C      0[a](#tfn5-jpr-10-933){ref-type="table-fn"}                                                         
  Time = 15min   −11.020                                       0.000   0.000         0.000             52.850    1   0.000
  Time = 10min   −9.904                                        0.000   0.000         0.001             69.864    1   0.000
  Time = 5min    −5.489                                        0.004   0.001         0.030             29.826    1   0.000
  Time = 0min    0[a](#tfn5-jpr-10-933){ref-type="table-fn"}                                                         

**Note:**

reference.

**Abbreviations:** C, sodium chloride; R1, remifentanil (0.1 μg/kg/min); R2, remifentanil (0.2 μg/kg/min); R3, remifentanil (0.3 μg/kg/min); SAS, sedation-agitation scale; CI, confidence interval; B, regression coefficient; OR, odds ratio; *df*, degrees of freedom.

###### 

Number (percentage) of VAS

  Emergence time   Score        Group C, n (%)   Group R1, n (%)   Group R2, n (%)   Group R3, n (%)
  ---------------- ------------ ---------------- ----------------- ----------------- -----------------
  0 min            0            25 (83.3%)       29 (96.7%)        29 (96.7%)        30 (100%)
  1                3 (10%)      1 (3.3%)         0                 0                 
  2                2 (6.7%)     0                1 (3.3%)          0                 
  5 min            0            3 (10%)          20 (66.7%)        13 (43.3%)        16 (53.3%)
  1                9 (30%)      8 (26.7%)        11 (36.7%)        12 (40%)          
  2                13 (43.3%)   2 (6.7%)         3 (10%)           2 (6.7%)          
  3                5 (16.7%)    0                2 (6.7%)          0                 
  5                0            0                1 (3.3%)          0                 
  10 min           0            1 (3.3%)         7 (24.1%)         8 (26.7%)         3 (10%)
  1                1 (3.3%)     14 (48.3%)       7 (23.3%)         13 (43.3%)        
  2                17 (56.7%)   8 (27.6%)        9 (30%)           11 (36.7%)        
  3                11 (36.7%)   0                4 (13.3%)         3 (10%)           
  5                0            0                2 (6.7%)          0                 
  15 min           0            1 (3.3%)         1 (3.3%)          3 (10%)           1 (3.3%)
  1                1 (3.3%)     7 (23.3%)        6 (20%)           4 (13.3%)         
  2                9 (30%)      17 (56.7%)       12 (40%)          16 (53.3%)        
  3                16 (53.3%)   5 (16.7%)        5 (16.7%)         6 (20%)           
  4                3 (10%)      0                3 (10%)           3 (10%)           
  5                0            0                1 (3.3%)          0                 

**Abbreviations:** C, sodium chloride; R1, remifentanil (0.1 μg/kg/min); R2, remifentanil (0.2 μg/kg/min); R3, remifentanil (0.3 μg/kg/min); VAS, visual analog scale.

###### 

Correlation between VAS and the dose and infusion time of remifentanil

  Parameters      B                                             OR       95%CI of OR   Hypothesis test                 
  --------------- --------------------------------------------- -------- ------------- ----------------- --------- --- -------
  VAS = 5.00      −8.913                                        0.000    0.000         0.001             94.411    1   0.000
  VAS = 4.00      −7.680                                        0.000    0.000         0.002             136.422   1   0.000
  VAS = 3.00      −5.494                                        0.004    0.001         0.013             87.361    1   0.000
  VAS = 2.00      −3.334                                        0.036    0.014         0.094             45.798    1   0.000
  VAS = 1.00      −1.689                                        0.185    0.079         0.430             15.304    1   0.000
  Group = R3      1.765                                         5.844    2.635         12.961            18.877    1   0.000
  Group = R2      1.645                                         5.183    1.990         13.503            11.346    1   0.001
  Group = R1      2.332                                         10.298   4.479         23.677            30.135    1   0.000
  Group = C       0[a](#tfn8-jpr-10-933){ref-type="table-fn"}                                                          
  Time = 15 min   −6.280                                        0.002    0.001         0.006             122.796   1   0.000
  Time = 10 min   −5.010                                        0.007    0.003         0.017             106.487   1   0.000
  Time = 5 min    −3.489                                        0.031    0.014         0.069             70.966    1   0.000
  Time = 0 min    0[a](#tfn8-jpr-10-933){ref-type="table-fn"}                                                          

**Note:**

reference.

**Abbreviations:** C, sodium chloride; R1, remifentanil (0.1 μg/kg/min); R2, remifentanil (0.2 μg/kg/min); R3, remifentanil (0.3 μg/kg/min); B, regression coefficient; OR, odds ratio; CI, confidence interval; VAS, visual analog scale; *df*, degrees of freedom.

###### 

Comparison of SBP, DBP, HR, R, and SPO2 before surgery, emergence, extubation, and at 2, 5, 10, and 15 min after extubation

  Parameters                                                                               SBP (mmHg)                                                   DBP (mmHg)                                                    HR (beats/min)                                               R (beats/min)                                                SPO~2~
  ------------------------- -------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------- ------------------------------------------------------------ ------------------------------------------------------------ --------------
  Group C                   Before surgery (baseline)                                      120.33 ± 12.72                                               70.53 ± 9.84                                                  77.73 ± 8.7                                                  17.57 ± 0.97                                                 95.6 ± 1.45
  Emergence                 142.87 ± 16.35[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   85.3 ± 11.92[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   93.6 ± 10.91[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    12.57 ± 0.82[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  Extubation                146.9 ± 16.05[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    86.7 ± 11.05[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   97.97 ± 12[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}      13.17 ± 0.7[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  2 min after extubation    142.33 ± 13.63[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   82.8 ± 11.12[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   94.2 ± 11.13[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    14.67 ± 0.71[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  5 min after extubation    135.4 ± 13.02[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    80.3 ± 10.22[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   91.2 ± 9.91[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}     15.73 ± 0.58[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  10 min after extubation   130.47 ± 11.99[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   75.8 ± 9.71[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    86.67 ± 9.77[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    16.73 ± 0.74[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  15 min after extubation   129.1 ± 13.18[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    74.5 ± 10.58[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   85.77 ± 9.88[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    17.13 ± 0.82[\*](#tfn10-jpr-10-933){ref-type="table-fn"}     100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  Group R1                  Before surgery (baseline)                                      126.93 ± 13.97                                               77.77 ± 10.36[††](#tfn13-jpr-10-933){ref-type="table-fn"}     77.03 ± 11.79                                                17.77 ± 0.94                                                 94.87 ± 2.24
  Emergence                 121.8 ± 16.27[††](#tfn13-jpr-10-933){ref-type="table-fn"}      72.57 ± 11.12^\*††^                                          78.63 ± 14.12[††](#tfn13-jpr-10-933){ref-type="table-fn"}     11.67 ± 1.06^\*\*††^                                         100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  Extubation                127.43 ± 16.5[††](#tfn13-jpr-10-933){ref-type="table-fn"}      76.17 ± 11.36[††](#tfn13-jpr-10-933){ref-type="table-fn"}    84.73 ± 13.71^\*\*††^                                         12.9 ± 0.88[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  2 min after extubation    129.43 ± 16.04[††](#tfn13-jpr-10-933){ref-type="table-fn"}     76.83 ± 11.55[†](#tfn12-jpr-10-933){ref-type="table-fn"}     83 ± 13.11^\*††^                                              14.27 ± 0.74^\*\*†^                                          100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  5 min after extubation    127.77 ± 13.78[†](#tfn12-jpr-10-933){ref-type="table-fn"}      73.67 ± 11.33^\*\*†^                                         82.7 ± 10.61^\*††^                                            15.6 ± 0.77[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  10 min after extubation   127.37 ± 17.98                                                 76 ± 13.67                                                   85.27 ± 11.28[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   16.63 ± 0.72[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   99.97 ± 0.18[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  15 min after extubation   129.77 ± 18.57                                                 75.1 ± 13.78                                                 84.73 ± 10.83[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   17.37 ± 0.56[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  Group R2                  Before surgery (baseline)                                      126.27 ± 14.48                                               77.93 ± 12.46[†](#tfn12-jpr-10-933){ref-type="table-fn"}      79.13 ± 11.2                                                 17.37 ± 0.96                                                 95.33 ± 1.83
  Emergence                 118.1 ± 14.21^\*\*††^                                          69.43 ± 10.62^\*\*††^                                        75.77 ± 13.78[††](#tfn13-jpr-10-933){ref-type="table-fn"}     12.33 ± 1.35[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  Extubation                124.77 ± 17.18[††](#tfn13-jpr-10-933){ref-type="table-fn"}     73.97 ± 11.87[††](#tfn13-jpr-10-933){ref-type="table-fn"}    81 ± 15.3[††](#tfn13-jpr-10-933){ref-type="table-fn"}         13.1 ± 1.16[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    99.9 ± 0.4[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}     
  2 min after extubation    123.8 ± 15.7[††](#tfn13-jpr-10-933){ref-type="table-fn"}       74.2 ± 12.1[††](#tfn13-jpr-10-933){ref-type="table-fn"}      82.47 ± 15.44[††](#tfn13-jpr-10-933){ref-type="table-fn"}     14.41 ± 0.95[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   99.87 ± 0.57[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  5 min after extubation    126.2 ± 18.14[†](#tfn12-jpr-10-933){ref-type="table-fn"}       74.3 ± 12.83[†](#tfn12-jpr-10-933){ref-type="table-fn"}      85.4 ± 14.43[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    15.37 ± 0.67^\*\*†^                                          99.83 ± 0.65[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  10 min after extubation   127.83 ± 17.63                                                 79.37 ± 12.55                                                85.87 ± 14.62[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   16.5 ± 0.82[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    99.8 ± 0.81[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}    
  15 min after extubation   130.77 ± 16.86                                                 78.83 ± 12.45                                                85.47 ± 14.99[\*](#tfn10-jpr-10-933){ref-type="table-fn"}     17.13 ± 0.73                                                 99.83 ± 0.65[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  Group R3                  Before surgery (baseline)                                      121.4 ± 12.84                                                71.8 ± 11.93                                                  77.6 ± 10.29                                                 17.9 ± 0.55                                                  95.9 ± 1.45
  Emergence                 114.03 ± 11.77^\*††^                                           65.8 ± 8.46^\*††^                                            71.73 ± 13.98^\*††^                                           11.53 ± 1.25^\*\*††^                                         99.97 ± 0.18[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  Extubation                118.5 ± 13.02[††](#tfn13-jpr-10-933){ref-type="table-fn"}      70.8 ± 8.96[††](#tfn13-jpr-10-933){ref-type="table-fn"}      79.23 ± 14.14[††](#tfn13-jpr-10-933){ref-type="table-fn"}     12.63 ± 1^\*\*†^                                             100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  2 min after extubation    121.37 ± 11.61[††](#tfn13-jpr-10-933){ref-type="table-fn"}     70.33 ± 10.6[††](#tfn13-jpr-10-933){ref-type="table-fn"}     78.87 ± 13.91[††](#tfn13-jpr-10-933){ref-type="table-fn"}     14 ± 0.91^\*\*††^                                            100 ± 0[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}        
  5 min after extubation    120.3 ± 10.68[††](#tfn13-jpr-10-933){ref-type="table-fn"}      73 ± 9.61[††](#tfn13-jpr-10-933){ref-type="table-fn"}        82.23 ± 13.58^\*††^                                           15.03 ± 0.81^\*\*††^                                         99.9 ± 0.4[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}     
  10 min after extubation   120.23 ± 8.91[††](#tfn13-jpr-10-933){ref-type="table-fn"}      73.1 ± 8.03                                                  82.7 ± 13.47[\*](#tfn10-jpr-10-933){ref-type="table-fn"}      16.37 ± 0.61^\*\*†^                                          99.97 ± 0.18[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   
  15 min after extubation   121.47 ± 8.54[†](#tfn12-jpr-10-933){ref-type="table-fn"}       74.13 ± 8.65                                                 82.07 ± 12.71[\*](#tfn10-jpr-10-933){ref-type="table-fn"}     17.33 ± 1.06[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   99.97 ± 0.18[\*\*](#tfn11-jpr-10-933){ref-type="table-fn"}   

**Notes:**

*P* \< 0.05,

*P* \< 0.01 vs before surgery within-group,

P \< 0.05,

P \< 0.01 vs group C.

**Abbreviations:** SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; R, respiratory rate; SPO~2~, saturation of pulse oximetry; C, sodium chloride; R1, remifentanil (0.1 μg/kg/min); R2, remifentanil (0.2 μg/kg/min); R3, remifentanil (0.3 μg/kg/min).
